Welcome to our dedicated page for Virios Therapeutics news (Ticker: VIRI), a resource for investors and traders seeking the latest updates and insights on Virios Therapeutics stock.
The VIRI news archive on Stock Titan provides historical coverage of Virios Therapeutics, Inc., a development-stage biotechnology company that focused on antiviral combination therapies for conditions such as fibromyalgia and Long-COVID. Company press releases repeatedly describe Virios Therapeutics’ strategy of combining antiviral agents with celecoxib to suppress herpesvirus replication and address diseases associated with a viral-triggered abnormal immune response.
Readers can review news items detailing clinical and corporate milestones. These include updates on the IMC-2 Long-COVID program, such as the Bateman Horne Center’s randomized, double-blind, placebo-controlled Phase 2a study and earlier exploratory work reporting reductions in fatigue, orthostatic intolerance, pain and anxiety with the valacyclovir and celecoxib combination. News releases also discuss the development status of IMC-1, a fixed-dosage combination of famciclovir and celecoxib that has received FDA Fast Track designation for fibromyalgia.
The archive further documents financing activities, including public offerings intended to support planned Long-COVID studies, as well as patent developments like the publication of a global patent application covering IMC-2 for Alzheimer’s and COVID-19. A key set of news items covers the announced business Combination between Virios Therapeutics and Wex Pharmaceuticals, Inc., the adoption of the Dogwood Therapeutics, Inc. name, and the transition of trading from the VIRI ticker to DWTX on the Nasdaq Capital Market.
By browsing these historical news releases, investors and researchers can trace how Virios Therapeutics’ antiviral programs evolved and how they were integrated into the broader Dogwood Therapeutics pipeline. This context can be useful for understanding the scientific and corporate background behind the current Dogwood Therapeutics, Inc. disclosures.
Virios Therapeutics (NASDAQ: VIRI) has begun enrolling participants in its exploratory Long-COVID trial, which seeks to assess the safety and effectiveness of its combination antiviral therapy, IMC-2 (valacyclovir + celecoxib). This study, backed by an unrestricted grant to the Bateman Horne Center, aims to address Long-COVID symptoms affecting an estimated 100 million individuals globally. The trial highlights the company's commitment to advancing treatments for chronic diseases linked to viral infections, building on its existing programs for conditions like fibromyalgia.
Virios Therapeutics, Inc. (Nasdaq: VIRI) reported its second-quarter financial results, highlighting completed patient dosing in the Phase 2b FORTRESS fibromyalgia study. Top-line results are expected in September 2022. The company believes that its antiviral candidate, IMC-1, may improve treatment for over 100 million fibromyalgia patients, with positive Phase 2a results supporting this potential. Financially, Q2 2022 net loss narrowed to $3.7 million, or $0.44 per share, with cash reserves of $7.7 million expected to fund operations through the end of 2022.
Virios Therapeutics (Nasdaq: VIRI) announced that its Chairman and CEO, Greg Duncan, will present at the Q3 Virtual Investor Summit on August 17, 2022. The presentation will cover the company's business strategy and key catalysts. Investors can register for the event, which will include 1x1 meetings with qualified investors. Virios is focused on developing antiviral therapies for chronic diseases like fibromyalgia and has candidates IMC-1 and IMC-2 in clinical trials. More details can be found on their website.
Virios Therapeutics, Inc. (NASDAQ: VIRI) will release its second quarter 2022 financial results on August 11, 2022, before market opening. A conference call is scheduled for the same day at 8:30 a.m. ET, where management will discuss the results and provide company updates. The company is developing antiviral therapies targeting chronic diseases, primarily focusing on fibromyalgia with its lead candidate, IMC-1, under a Phase 2a clinical trial. Virios is also pursuing IMC-2 for Long COVID with an unrestricted grant to the Bateman Horne Center.
Virios Therapeutics (Nasdaq: VIRI) announced pilot study results at the University of Alabama, highlighting a significant association between gastric herpes virus infection and functional gastrointestinal disorders (FGID) such as irritable bowel syndrome and fibromyalgia. The study, published in Infection, found a marked increase in HSV-1 presence in patients with FGIDs. This suggests potential for combination antiviral therapies like IMC-1 to treat these chronic conditions. The company aims to further explore this association and enhance treatment visibility in the medical community.
Virios Therapeutics (NASDAQ: VIRI) completed enrollment in its Phase 2b FORTRESS study for IMC-1, a treatment aimed at fibromyalgia, with top-line data expected in September 2022. The company reported first-quarter financial results showing a net loss of $4.0 million ($0.48 per share) versus a loss of $3.1 million ($0.37 per share) in Q1 2021, driven by rising R&D costs. As of March 31, 2022, cash reserves stood at $11.4 million, sufficient to support operations through 2022. The firm is also pursuing IMC-2 for Long COVID symptoms under a grant to the Bateman Horne Center.
Virios Therapeutics (NASDAQ: VIRI) will announce its Q1 2022 financial results on May 12, 2022, before the market opens. A conference call will follow at 8:30 a.m. ET for management to discuss the results and provide updates. Virios focuses on antiviral therapies for chronic diseases, particularly fibromyalgia. Its lead candidate, IMC-1, has received fast track designation from the FDA and is currently in a clinical trial. The company is also pursuing IMC-2 for Long COVID management. Visit www.virios.com for more details.
Virios Therapeutics (Nasdaq: VIRI) has completed enrollment for its Phase 2b FORTRESS study, evaluating the efficacy of IMC-1, a combination antiviral therapy designed to treat fibromyalgia. The study aims to assess pain reduction among over 400 patients and is expected to yield top-line results in September 2022. IMC-1 combines famciclovir and celecoxib, targeting herpes virus suppression, and has received fast track designation from the FDA. Previous studies showed promise, with significant pain relief and better tolerance compared to placebo.
Virios Therapeutics (Nasdaq: VIRI) reported its fourth quarter and full-year financial results for 2021, highlighting significant operational progress. The Company aims to release top-line results from the Phase 2b FORTRESS study on fibromyalgia in Q3 2022. Virios also announced plans for a new exploratory study of IMC-2 targeting Long COVID, with cash reserves of $14.0 million expected to sustain operations through Q1 2023. R&D expenses increased to $10.8 million in 2021, while the net loss for the year was $16.0 million.
Virios Therapeutics (Nasdaq: VIRI) will release its fourth quarter and full year 2021 financial results on